Autoimmune lymphoproliferative syndrome (ALPS) is a genetic disorder of lymphocyte homeostasis due to impaired apoptosis. It is characterized by nonmalignant lymphoproliferation, autoimmune cytopenia, and increased risk of lymphoma. In addition, the presence of increased CD3
(TCRab 1 ) double-negative T (DNT) cells is a hallmark of this disease. 1 Genetic analysis has identified defects in the genes encoding Fas, 2, 3 Fas-ligand, 4 and caspase 10 5 in a small number of patients with ALPS. According to the updated diagnostic criteria, patients with autoimmune lymphoproliferation but marginally elevated or normal TCRab 1 DNT cells are classified as suffering from ALPS-related disorders. Besides autoimmunity, such patients may present with recurrent infections. 1 Among a proportion of these patients, mutations in caspase 8, 6 NRAS, 7 and KRAS 8 have been identified. ALPS was initially regarded as a very rare disease, but recent studies show that it may be more common than previously thought. It is estimated that around one-third of patients with ALPS(-related) disease remain undefined genetically.
Ras guanyl nucleotide releasing protein 1 (RasGRP1) is a member of Ras guanine nucleotide exchange factors, and specifically activates Ras through the exchange of bound guanosine diphosphate for guanosine triphosphate. It is highly expressed in T cells, and to a lesser extent in B and natural killer cells. Serial studies have demonstrated that RasGRP1 is essential for T-cell development and function through coupling T-cell receptor (TCR) to Ras-mitogen-activated protein kinase signaling pathway. Upon TCR engagement, linker for activation of T cells (LAT) becomes phosphorylated and recruits phospholipase Cg1 along with other molecules. Activated phospholipase Cg1 then hydrolyses phosphatidylinositol-(4,5)-bisphosphate into diacylglycerol (DAG) and inositol-1,4,5-trisphosphate. DAG further activates RasGRP1 and then leads to the activation of extracellular signal-regulated kinase (ERK) 1/2, finally the transcription of genes involved in cell proliferation, survival, and other cellular processes. [9] [10] [11] [12] Previous animal studies demonstrated that RasGRP1-deficient mice developed autoimmune lymphoproliferative disease with phenotypes of lymphadenopathy, splenomegaly, and presence of antinuclear autoantibody (ANA). [13] [14] [15] [16] The underlying mechanism remains unclear, but the condition was reported to be T-celldependent, based on the fact that RasGRP1-deficient nude mice have significantly reduced serum autoantibodies. 14 Furthermore, patients with systemic lupus erythematous (SLE) were demonstrated to have aberrant RASGRP1 splice variants, which was correlated with lower levels of RasGRP1 protein in patients' T cells and diminished RasGRP1 activity. 17 These findings strongly suggest that RasGRP1 dysfunction is closely associated with autoimmune disease.
In this study, we report 2 siblings born to nonconsanguineous parents, who presented with ALPS-like disease, including chronic lymphadenopathy, hepatosplenomegaly, autoimmune hemolytic anemia, immune thrombocytopenia, and the presence of ANA and other autoantibodies, but normal TCRab 1 DNT cells. They also suffered from recurrent infections. With wholeexome sequencing, compound heterozygous mutations of RASGRP1 were identified in both patients, resulting in impaired ERK activation, T-cell activation and proliferation, as well as activation-induced cell death of T cells.
METHODS

The family and ethical approval
The 2 patients, their parents, and age-matched controls were included in this study. The study was approved by the Institutional Review Board of the University of Hong Kong-Shenzhen Hospital (IRB reference no. 201603). The informed consent was obtained from the parents for the children and themselves to participate in this study.
Genetic study
Genomic DNA from the patients and parents were extracted from PBMCs. Library preparation, exome capture, and whole-exome sequencing were performed at the Centre for Genomic Sciences, University of Hong Kong. Library preparation and exome capture were done using Illumina TruSeq DNA Library Preparation Kit. Exome sequencing was performed on Illumina HiSeq2000 platform (Illumina, San Diego, Calif). Sanger sequencing was performed to confirm the genetic variations identified by exome sequencing. Additional detailed methods regarding the whole-exome sequencing are provided in this article's Online Repository at www.jacionline.org.
Preparation of PBMCs
The PBMCs were isolated from whole blood obtained from the patients, family members, and healthy normal controls by Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) gradient centrifugation. The cells were cultured in RPMI 1640 medium plus 10% FBS.
Flow cytometry
The following mAbs were used in this study: anti-CD3, anti-CD4, anti-CD8, anti-CD19, anti-TCRab, anti-TCRgd, anti-CD69, anti-active caspase 3, anti-CD21, anti-CD27, anti-Foxp3 (all from BD Biosciences, San Diego, Calif), anti-CD38, anti-IgD, anti-Ki67 (BioLegend), and anti-RasGRP1 (antibodies-online). For surface staining, the cells were stained with the specific antibodies. For intracellular staining, cells were fixed by Lysing Solution, permeabilized by Permeabilizing Solution 2 (both from BD Biosciences), and then labeled with the indicated antibodies. All data were acquired on a BD FACSAria machine with FACS Diva (BD Biosciences) and analyzed using FlowJo software (TreeStar, Ashland, Ore).
Cell proliferation was examined using carboxyfluorescein succinimidyl ester dilution assay as we previously described. 18 Briefly, PBMCs were stained first with 1 mM carboxyfluorescein succinimidyl ester (Invitrogen, Carlsbad, Calif), and then stimulated with LEAF purified anti-CD3 and anti-CD28 antibodies (both from BioLegend, San Diego, Calif). After 4 days, cells were collected and stained with anti-CD4 and anti-CD8 antibodies before the examination by flow cytometry. The number of cell divisions and percentage of cells divided were analyzed using FlowJo software. The intracellular expression of Ki67 was also detected as a surrogate marker for cell proliferation. To examine cell apoptosis, PBMCs were first stimulated with anti-CD3 and anti-CD28 antibodies, or PMA and ionomycin. After 2 days, apoptotic cells were detected with annexin V-fluorescein isothiocyanate and propidium iodide staining by flow cytometry. The percentage of cell death was calculated as [1 2 (% of live cells with stimulation/% of live cells without stimulation)] 3 100. The intracellular expression of active caspase 3 was also examined for cell apoptosis.
Determination of ERK activation by examining protein phosphorylation
To examine ERK activation, 1 million PBMCs were stimulated with 50 ng/ mL PMA for 5 minutes. Cells were then determined for the protein phosphorylation by flow cytometry as described earlier. 19 Briefly, cells were fixed by Fix Buffer I, permeabilized by Perm Buffer III (both from BD Biosciences), and stained with anti-pEKR1/2 (pT202/pY204, BD Biosciences) to detect phosphorylated ERK1/2 expression. Samples were analyzed for the percentage of phospho-protein-positive population by flow cytometry. The increase in the percentage of phospho-protein expression in stimulated cells relative to resting cells was calculated.
Cytokine quantitation
One million PBMCs were stimulated with 1 mg/mL LEAF purified anti-CD3 and anti-CD28 antibodies (both from BioLegend) for 2 days. The supernatants were collected and then determined for the production of IL-10 by using BD Cytometric Bead Array kit (BD Biosciences) according to the manufacturer's instruction. The data were acquired on a BD FACSAria (BD Biosciences) and analyzed using FCAP Array software.
Structural analysis of RasGRP1
The crystal structure of RasGRP1 (4L9M from the protein data bank) was used as the template, which was determined by X-ray diffraction at a resolution of 3.0 A. The amino acid residue at coordinate 214 was mutated for variant Thr241Ile. The structures were analyzed with Swiss-PdbViewer. The residue 214, together with certain nearby ones within 6 A, was illustrated. For clear demonstration of interresidue relationship, some residues were highlighted in the indicated colors with the computed hydrogen bonds being labeled.
RESULTS
The patients
The 2 siblings comprising a sister with her younger brother came from a nonconsanguineous kindred with no significant family history (Fig 1, A) . At age 2 years, the sister had immune thrombocytopenia responsive to intravenous immunoglobulin treatment (Table I) . She further experienced 2 episodes of chronic immune thrombocytopenia at the age of 5 and 8 years, respectively, which were refractory to IVIG and steroid therapy. J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 2
At age 7 years, she had autoimmune hemolytic anemia. From age 5 years, she had documented chronic lymphadenopathy and hepatosplenomegaly (Fig 1, B and C) . During the first 4 years, the patients had several episodes of pneumonia but without detailed investigation. From age 4 years, she had multiple episodes of pneumonia caused by a spectrum of pathogens including Mycoplasma pneumonia, Moraxella catarrhalis, Hemophilus influenza, Staphylococcus aureus, and Candida albicans. The patient also developed leiomyoma in the right adrenal gland and left lobe of liver at the age of 5 years, which were resected.
At age 1 month, the brother had hemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection. Like his sister, the brother also had documented chronic lymphadenopathy and hepatosplenomegaly since age 1 year (Table I) . At age 10 and 17 months, he further developed autoimmune hemolytic anemia, which was treated with steroid and mycophenolate mofetil. He also had several episodes of infections with EBV, Staphylococcus aureus, and Mycoplasma pneumonia. He further experienced pulmonary aspergillosis and lymph node tuberculosis at age 7 and 17 months, respectively. Investigations showed the presence of hypergammaglobulinemia, ANA and other autoantibodies, and normal IgE level in both patients (Table I) . They are now stable and followed-up in our clinic.
Immunophenotype
Because both patients presented with chronic lymphoproliferation and autoimmune disease, ALPS was first considered for the working diagnosis. Thus, the presence of TCRab 1 DNT cells was examined. As shown in Fig 1, D, low B cells was markedly increased in the patients (Fig 1, E) .
Whole-exome sequencing identified compound heterozygous RASGRP1 mutations
To dissect the genetic cause, whole-exome sequencing was performed for the 2 patients and their parents. A total of 10,163 rare variants were detected in the family, of which 645 were missense, nonsense, splice-site, or frameshift variants. Based on a stepwise approaching algorithm routinely practiced in our laboratory, bioinformatics analysis was performed and finally 3 genes that contain either homozygous or compound heterozygous mutations were considered of interest genetically (see Tables E1   FIG 2 . Novel compound heterozygous mutations in RASGRP1 were identified in the patients. A, Compound heterozygous mutations in both patients and heterozygous carrier in the parents were shown in genomic RASGRP1 DNA. B, The schematic structure of RasGRP1. The mutations are located in the Cdc25 domain. C, Phylogenetic analysis indicated that the positions of mutations are highly conserved across different species. and E2 in this article's Online Repository at www.jacionline.org). The detailed information on exome sequencing and analysis is provided in this article's Online Repository at www.jacionline. org.
The tissue distributions and functions of the 3 genes were further analyzed. Of these, RasGRP1 is a Ras guanine nucleotide exchange factor and mainly expressed in lymphocytes. Through its role in TCR signaling pathway, RasGRP1 is essential for Tcell development and homeostasis. Previous animal studies demonstrated the contribution of RasGR1 in autoimmune disease. Therefore, RASGRP1 mutations were regarded as the most likely candidate causal mutations for the 2 patients. Sanger sequencing confirmed the heterozygous mutations of RASGRP1 in the patients' father (c.641C>T, p.T214I) and mother (c.964A>T, p.K322X), and the compound heterozygous nature in the patients (Fig 2, A) , consistent with the original sequencing finding (see Fig E4 in this article' s Online Repository at www. jacionline.org). The 2 mutations are located in the Cdc25 domain (Fig 2, B) and not observed in any of the currently available public databases. Phylogenetic analysis indicated that the positions of the 2 mutations are highly conserved across different species (Fig 2, C) . Both the 2 mutations were predicted to be damaging. Structural analysis showed that a hydrogen bond present between Thr214 and Asn290 in the wild-type RasGRP1 was broken by the Thr214Ile mutation (see Fig E5 in this article' s Online Repository at www.jacionline.org), which might affect Ras binding and catalytic activity of RasGRP1 because the residues are located in the catalytic domain. Taken together, considering the similarity between the phenotype of patients described here and that of RasGRP1-deficient mice (see Table E3 in this article's Online Repository at www.jacionline.org), we hypothesized that the compound heterozygous RASGRP1 mutations are the causal mutations for the 2 patients.
Normal RasGRP1 expression, but impaired ERK activation, in patient cells
We next examined whether the mutations affect the expression of RasGRP1. As shown in Fig 3, A, comparable level of RasGRP1 protein was detected between the patients and controls. Because RasGRP1 is expressed in both T and B cells, we further examined the protein expression in the lymphocyte subsets. It was shown that the patients had a similar level of RasGRP1 as the controls in either T or B cells (see Fig E6 in this article' s Online Repository at www.jacionline.org), which indicates that the compound heterozygous mutations did not alter the protein expression, likely because of 1 mutation being missense.
RasGRP1 acts downstream of antigen receptors of lymphocytes. Upon cognate peptide ligation of lymphoctes, the intracellular messenger DAG is generated and then activates RasGRP1, leading to ERK activation. The effect of RASGRP1 mutation on ERK activation was further examined. PMA is a synthetic analog of DAG and used in the experiments. Upon PMA engagement, almost all the ERK was phosphorylated in the lymphocytes of normal controls and parents. However, only a negligible level of ERK activation was observed in the patients' cells (Fig 3, B) . PMA-induced ERK phosphorylation was further examined in T and B cells, respectively. It was found that the impaired ERK activation induced by PMA was observed only in T cells, but not B cells, of the patients. Instead, PMA-induced comparable level of ERK phosphorylation in B cells between the patients and normal controls (see Fig E7 in this article' s Online Repository at www.jacionline. org). Taken together, normal RasGRP1 expression, but impaired ERK activation, was revealed in patient cells with compound heterozygous mutations of RasGRP1. 
Impaired activation and proliferation in patient T cells
It is well known that RasGRP1 activates the ERK/mitogenactivated protein kinase cascade through coupling TCR to Ras signaling pathway to regulate T-cell activation and proliferation. After demonstrating that RASGRP1 mutations blocked ERK phosphorylation, we next investigated T-cell activation induced by TCR ligation. The PBMCs were stimulated with anti-CD3 and anti-CD28 antibodies and then examined for CD69 expression. As shown in Fig 4, A, the activation of T cells was significantly depressed in the patients compared with normal controls, as evidenced by the much less percentage of T cells expressing CD69 as well as a significantly lower intensity of CD69 expression level. Of T cells, both CD4 and CD8 T cells showed markedly impaired activation in the patients (see Fig E8 in this article's Online Repository at www.jacionline.org). The cell proliferation was further investigated with carboxyfluorescein succinimidyl ester dilution assay. As indicated in Fig 4, B, after stimulation with anti-CD3 and anti-CD28 antibodies, nearly no lymphocytes were demonstrated to undergo proliferation in the patients, in significant contrast to normal controls, where about 3 to 5 cellular divisions were detected in more than half of total lymphocytes. Of T cells, both CD4 and CD8 T did not show proliferation in the patients (see Fig E9 in this article' s Online Repository at www.jacionline.org). The cell proliferation was also examined by another method using Ki67 as a surrogate marker. 20 Similarly, significant impairment of T-cell proliferation was detected in the patients compared with normal controls (see Fig  E10 in this article' s Online Repository at www.jacionline.org). The impaired cell activation and proliferation made the transfection of patient T cells with wild-type RasGRP1-expressing lentivirus quite difficult in our rescue study, whereas the transfection of normal control T cells was successful as an internal control (see Fig E11 in this article' s Online Repository at www. jacionline.org). Thus, it made the rescue assay with patient cells unfeasible despite of repeated trials.
Impaired activation-induced cell death in patient T cells
Control of apoptosis in lymphocytes is particularly important, because autoreactive cells must be deleted to avoid autoimmune disorders. RasGRP1 is involved in cell survival through the Ras signaling. The effect of RASGRP1 mutations on T-cell viability was further examined. The PBMCs were stimulated with anti-CD3 and anti-CD28 antibodies and then examined for the activation-induced cell death of T cells. As shown in Fig 5, A, after TCR-mediated activation, the intracellular expression of active caspase 3 was markedly decreased in both patients' cells compared with that in normal controls. Of T cells, both CD4 and CD8 T cells showed significantly impaired activationinduced cell death in the patients (see Fig E12 in this article's Online Repository at www.jacionline.org). The cell apoptosis was further examined by using annexin V and propidium iodide staining. It was also shown that the patient had remarkable decrease in cell apoptosis compared with normal controls (Fig 5, B) . IL-10 plays an important role in the induction of tolerance and maintenance of immunological homeostasis. The ability of IL-10 production in the patients' cells was next examined. In response to TCR stimulation, the patients' cells produced markedly lower IL-10 as compared with normal controls (Fig 5, C) .
DISCUSSION
In this study, we identified novel compound heterozygous RASGRP1 mutations in 2 siblings with ALPS-like disorder with parents being heterozygous carriers. One of the mutations is hypomorphic, resulting in normal RasGRP1 expression but impaired function. The 2 siblings had chronic lymphadenopathy, hepatosplenomegaly, autoantibodies including ANA, and autoimmune cytopenia, but normal TCRab 1 DNT cells. They also suffered from recurrent infections.
Series of animal studies have already demonstrated that RasGRP1-deficient mice with either complete deletion 13, 14 or truncation 15 of RasGRP1 developed autoimmune lymphoproliferative disorder with the phenotypes of lymphadenopathy, splenomegaly, and the presence of ANA. The similarity between the clinical, immunological, and cellular phenotypes of patients described here and those of RasGRP1-deficient mice (see Table  E3 ) strongly suggests the causative nature of RASGRP1 mutations in our patients. Indeed, in humans, RasGRP1 has been shown to be associated with some autoimmune disorders. SLE is a complex autoimmune disease characterized by high levels of ANA autoantibodies. A subset of patients with SLE was shown to have aberrant RasGRP1 splice variants, which was correlated with defective RasGRP1 expression in their T cells and diminished RasGRP1 activity.
17 RASGRP1-linked single nucleotide variants were also shown to be associated with autoimmune diabetes and thyroid disease. 21, 22 In addition, the phenotype of RasGRP1 deficiency is similar in many aspects to that of LAT mutation. LAT is located upstream of RasGRP1 in TCR signal pathway and, together with RasGRP1, contributes to the signaling transmission and final biological FIG 5 . Impaired activation-induced cell death in patient T cells. A, After stimulation with anti-CD3 and anti-CD28 antibodies, intracellular expression of active caspase 3 in lymphocytes was examined. B, PBMCs were stimulated with PMA and ionomycin. Lymphocyte apoptosis was examined using annexin V and propidium iodide staining. C, PBMCs were stimulated with anti-CD3 and anti-CD28 antibodies. IL-10 production in the supernatants was examined.
activity. Previous studies showed that LAT deficiency inhibited Tcell development yet induced autoimmune lymphoproliferation. The T cells from LAT mutant mice also showed defective TCR signaling and apoptosis. 23, 24 Taken together, these findings reveal that the LAT-RasGRP1-Ras signaling axis in T cells plays critical roles in maintaining self-tolerance and homeostasis. Dysfunction of such intracellular signal proteins contributes to the development of autoimmune disorders.
RasGRP1 plays important roles in the host immune defense. Both our data and previous in vivo studies have demonstrated that RasGRP1 deficiency impaired T-cell function including activation and proliferation. 10, 25, 26 In addition, RasGRP1-deficient T cells showed diminished cytokine production upon cognate antigen stimulation. 27 For the innate immunity, RasGRP1 was reported to be required for human natural killer cell function. Knockdown of RasGRP1 blocked cytokine production and cytotoxicity of natural killer cells.
28 RasGRP1-deficient gdT cells were also shown to have diminished IL-17 expression besides defective proliferation. 29 Therefore, the impaired adaptive and innate immunity would render the host susceptible to various infections, which at least partly explains why our patients with RasGRP1 deficiency developed multiple infections. Indeed, a previous study also demonstrated that RasGRP1-deficient mice showed weakened immune system and poor pathogen-specific T-cell response, leading to delayed pathogen clearance when challenged with bacteria and viruses. 30 Herein, the patients developed ALPS-like disease despite the impaired proliferation of lymphocytes. However, our data and previous report showed that the regulatory T cell is intact, and even the function is enhanced in RasGRP1-deficient mice. 31 To clarify the mechanism underlying the autoimmune lymphoproliferation, we investigated the apoptosis in our patients. A properly functioning immune system is dependent on apoptosis at every stage of lymphocyte development. Apoptosis plays essential roles to maintain tolerance and homeostasis, because self-reactive lymphocytes must be deleted by this means to avoid autoimmune disorders. 32, 33 In this study, we showed that patients' cells had markedly impaired activation-induced cell death, which is compatible with previous findings in the mouse study. 10, 14 In addition, the patients were shown to have markedly higher CD21 low B cells compared with the normal controls. It has been reported that CD21 low B cells contain mostly autoreactive clones, and are found enriched in patients with autoimmune disorders. Most CD21 low B cells express autoreactive antibodies that recognize nuclear and cytoplasmic structures. 34 We further demonstrated that TCR-stimulated IL-10 production was markedly depressed in the patients. IL-10 plays an important role in the induction of tolerance and maintenance of immunological homeostasis. 35 Collectively, we speculate that the defective apoptosis, IL-10 expression, and increased CD21 low B cells may contribute to the development of autoimmune lymphoproliferative phenotype in the patients.
RasGRP1 couples TCR to Ras signaling pathway in T cells, and participates in various cellular processes including cell activation and proliferation. 36, 37 In accordance with this, both our data and previous mouse studies revealed that RasGRP1-deificient thymocytes and T cells showed impaired Ras-ERK signaling, leading to defective cell activation and proliferation in response to DAG and TCR stimulation. 10, 25, 26 RasGRP1 is highly expressed in T cells, though it is also detected in B cells to a lesser extent. In B cells, both RasGRP1 and RasGRP3 act downstream of BCR. RasGRP1-deficient mice do not have a block in B-cell development. Only B cells deficient in both RasGRP1 and RasGRP3 showed defective proliferative response. 10, 14, 38 Compatible with this, we found that our patients' B cells showed normal activation upon stimulation.
In summary, we identified loss-of-function mutations of RASGRP1 in 2 siblings with ALPS-like disease. The mutations impair TCR signaling, leading to defective T-cell activation and proliferation, as well as impaired activation-induced cell death of T cells. The similarity between the phenotype of our patients and that of RasGRP1-deficient mice, as well as that of mutation of LAT, a component upstream of RasGRP1 in TCR signaling, clearly indicates the causative nature of RASGRP1 mutations in our patients. We propose to investigate the intracellular proteins involved in the TCR signaling pathway in similar patients but with unknown genetic cause.
Addendum
During the revision period of our manuscript, an article by Salzer et al 39 was published advance online in Nature Immunology, which reported that 1 patient with homozygous null mutation of RasGRP1 had bacterial and viral infections. It is a different clinical phenotype compared with that in the mouse model with similar RasGRP1 null mutation. In our study, we demonstrated 2 patients with RasGRP1 hypomorphic mutation who developed ALPS-like phenotype in addition to recurrent infections, which is almost the same as what has been reported in RasGRP1-deficient mice with either complete deletion or truncation of RasGRP1 [13] [14] [15] (Table E3 ). Our findings are also compatible with the reported association of RasGRP1 with autoimmune disorders in humans, such as SLE, and autoimmune diabetes and thyroid disease. 17, 21, 22 The reason why the patient described by Salzer et al 39 did not show autoimmune lymphoproliferative features warrants further investigation. 
METHODS
Whole-exome sequencing and bioinformatics analysis
The whole-exome sequencing was performed at the Centre for Genomic Sciences, University of Hong Kong. Library preparation and exome capture were done with Illumina TruSeq DNA Library Preparation Kit. Exome sequencing was performed on Illumina HiSeq2000 platform (Illumina). Using software from Illumina (bcl2fastq), sequencing reads were assigned into individual samples, with each sample having an average sequencing volume of 6.8 Gbp. On average, 91% of the bases achieved a quality score of Q30 (accuracy of a base call to be 99.9%). After removal of adapter sequences, lowquality reads, and reads with more than 10% of unknown nucleotides, the clean reads were aligned to the reference human genome build hg19 using Burrows-Wheeler Aligner.
E1 Single nucleotide polymorphisms/Indels were called using GATK. E2 Annotation of all variants was performed using ANNOVAR.
E3
Only good-quality variants were included for further analysis. The criteria used included variant mapping quality greater than or equal to 30, coverage depth equal to or greater than 5-fold in both patients, and genotype quality greater than or equal to 30. Taking into consideration the rarity of the phenotype of the patients, we excluded the common variants with population allele frequency higher than 1% in the public databases including the 1000 Genomes Project, dbSNP, NHLBI GO Exome Sequencing Project, and Exome Aggregation Consortium (ExAC: http://exac.broadinstitute.org/).
Whole-exome sequencing detected 10,163 rare variants in this family in total. Of these, 645 were missense, nonsense, splice-site, or frameshift variants by the function filter we adopted on SNV/Indels (Table E1) . Based on a stepwise approaching algorithm routinely practiced in our laboratory, bioinformatics analysis was performed and finally 3 genes that contain either homozygous or compound heterozygous mutations were considered of interest genetically. One homozygous missense mutation in PLIN4 was detected on both patients while parents were heterozygous carrier. Two genes (RASGRP1 and CCDC74B) with compound heterozygous mutations were detected on both patients and parents were also carriers (Table E2 ). There is no de novo mutation detected in either patient.
The tissue distributions and functions of the 3 genes were further analyzed (Table E2 ). Of these, RasGRP1 is a Ras guanine nucleotide exchange factor and mainly expressed in lymphocytes. Through its role in TCR signaling pathway, RasGRP1 is essential for T-cell development and homeostasis. Previous animal studies have demonstrated the contribution of RasGR1 in autoimmune disease. Therefore, the compound heterozygous mutations in RASGRP1 were regarded as the most likely candidate causal mutations for the 2 patients. The 2 children inherited a Threonine to Isoleucine missense mutation (T214I) from their father and a nonsense (K322X) mutation from their mother. The 2 mutations are not observed in any of the currently available public databases. The positions of the 2 mutations are highly conserved across different species. Threonine to Isoleucine substitution at position 214 of RasGRP1 was predicted to be damaging or deleterious by all the bioinformatics tools including Polyphen, SIFT, LRT, LR, MutationTaster, Mutation Assessor, and RadialSVM. K322X mutation occurs in the eighth exon of this 17-exon gene and predicted as damaging. This early stop codon may cause nonsense-mediated decay of the mRNA transcript from this allele and lead to abolition of protein expression. Sanger sequencing confirmed the heterozygous mutations of RASGRP1 in the patients' father (c.641C>T, p.T214I) and mother (c.964A>T, p.K322X), and the compound heterozygous nature in the patients. were determined by flow cytometry. 
